Search

Your search keyword '"Tani, Monica"' showing total 6 results
Start Over Author "Tani, Monica" Publication Type Electronic Resources
6 results on '"Tani, Monica"'

1. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia

Author

MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Tam, Constantine S, Opat, Stephen, D'Sa, Shirley P, Jurczak, Wojciech, Lee, Hui-Peng, Cull, Gavin, Owen, Roger G, Marlton, Paula, Wahlin, Björn E, Garcia-Sanz, Ramon, McCarthy, Helen, Mulligan, Stephen P, Tedeschi, Alessandra, Castillo, Jorge J, Czyz, Jaroslaw, Fernández de Larrea, Carlos, Belada, David, Libby, Edward N, Matous, Jeffrey V, Motta, Marina, Siddiqi, Tanya, Tani, Monica, Trněný, Marek, Minnema, Monique C, Buske, Christian, Leblond, Véronique, Treon, Steven P, Trotman, Judith, Wu, Binghao, Yu, Yiling, Shen, Zhirong, Chan, Wai Y, Schneider, Jingjing, Allewelt, Heather, Cohen, Aileen, Dimopoulos, Meletios-Athanasios A, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Tam, Constantine S, Opat, Stephen, D'Sa, Shirley P, Jurczak, Wojciech, Lee, Hui-Peng, Cull, Gavin, Owen, Roger G, Marlton, Paula, Wahlin, Björn E, Garcia-Sanz, Ramon, McCarthy, Helen, Mulligan, Stephen P, Tedeschi, Alessandra, Castillo, Jorge J, Czyz, Jaroslaw, Fernández de Larrea, Carlos, Belada, David, Libby, Edward N, Matous, Jeffrey V, Motta, Marina, Siddiqi, Tanya, Tani, Monica, Trněný, Marek, Minnema, Monique C, Buske, Christian, Leblond, Véronique, Treon, Steven P, Trotman, Judith, Wu, Binghao, Yu, Yiling, Shen, Zhirong, Chan, Wai Y, Schneider, Jingjing, Allewelt, Heather, Cohen, Aileen, and Dimopoulos, Meletios-Athanasios A

Published
2024

2. High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the GIMEMA phase II LLC1518 - 'Veritas' study

Author

Mauro, Francesca R, Starza, Irene Della, Messina, Monica, Reda, Gianluigi, Trentin, Livio, Coscia, Marta, Sportoletti, Paolo, Orsucci, Lorella, Arena, Valentina, Casaluci, Gloria Margiotta, Marasca, Roberto, Murru, Roberta, Laurenti, Luca, Ilariucci, Fiorella, Stelitano, Caterina, Mannina, Donato, Massaia, Massimo, Rigolin, Gian Matteo, Scarfò, Lydia, Marchetti, Monia, Levato, Luciano, Tani, Monica, Arcari, Annalisa, Musuraca, Gerardo, Deodato, Marina, Galieni, Piero, Patrizi, Valeria Belsito, Gottardi, Daniela, Liberati, Anna Marina, Giordano, Annamaria, Molinari, Maria Chiara, Pietrasanta, Daniela, Mattiello, Veronica, Visentin, Andrea, Vitale, Candida, Albano, Francesco, Neri, Antonino, De Novi, Lucia Anna, De Propris, Maria Stefania, Nanni, Mauro, Del Giudice, Ilaria, Guarini, Anna, Fazi, Paola, Vignetti, Marco, Piciocchi, Alfonso, Cuneo, Antonio, Foà, Robin, Laurenti, Luca (ORCID:0000-0002-8327-1396), Mauro, Francesca R, Starza, Irene Della, Messina, Monica, Reda, Gianluigi, Trentin, Livio, Coscia, Marta, Sportoletti, Paolo, Orsucci, Lorella, Arena, Valentina, Casaluci, Gloria Margiotta, Marasca, Roberto, Murru, Roberta, Laurenti, Luca, Ilariucci, Fiorella, Stelitano, Caterina, Mannina, Donato, Massaia, Massimo, Rigolin, Gian Matteo, Scarfò, Lydia, Marchetti, Monia, Levato, Luciano, Tani, Monica, Arcari, Annalisa, Musuraca, Gerardo, Deodato, Marina, Galieni, Piero, Patrizi, Valeria Belsito, Gottardi, Daniela, Liberati, Anna Marina, Giordano, Annamaria, Molinari, Maria Chiara, Pietrasanta, Daniela, Mattiello, Veronica, Visentin, Andrea, Vitale, Candida, Albano, Francesco, Neri, Antonino, De Novi, Lucia Anna, De Propris, Maria Stefania, Nanni, Mauro, Del Giudice, Ilaria, Guarini, Anna, Fazi, Paola, Vignetti, Marco, Piciocchi, Alfonso, Cuneo, Antonio, Foà, Robin, and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

The GIMEMA phase II LLC1518 VERITAS trial investigated the efficacy and safety of frontline, fixed-duration venetoclax and rituximab (VenR) combination in young (≤65 years) and fit patients with chronic lymphocytic leukemia (CLL) and unmutated IGHV and/or TP53 disruption. Treatment consisted of the Ven ramp-up, six-monthly courses of the VenR combination, followed by six monthly courses of Ven single agent. A centralized assessment of measurable minimal residual disease (MRD) was performed on the peripheral blood (PB) and bone marrow (BM) by ASO-PCR at the end of treatment (EOT) and during the follow-up. The primary endpoint was the complete remission (CR) rate at the EOT. Seventy-five patients were enrolled; the median age was 54 years (range 38-65), 96% had unmutated IGHV, 9 (12%) had TP53 disruption, and 4% were IGHV mutated with TP53 disruption. The overall response rate (ORR) at the EOT was 94.7%, with a CR rate of 76%. An undetectable (u) MRD was recorded in 69.3% of patients in the PB and 58.7% in the BM. The 12-month MRD-free survival in the 52 patients with uMRD in the PB at the EOT was 73.1%. After a median follow-up of 20.8 months, no disease progressions were observed. Three patients have died, two due to Covid-19 and 1 to tumor lysis syndrome. The first report of the VERITAS study shows that frontline VenR was associated with a high rate of CRs and durable responses with uMRD in young patients with CLL and unfavorable genetic characteristics.

Published
2023

3. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

Author

MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Dimopoulos, Meletios A, Opat, Stephen, D'Sa, Shirley, Jurczak, Wojciech, Lee, Hui-Peng, Cull, Gavin, Owen, Roger G, Marlton, Paula, Wahlin, Björn E, Garcia-Sanz, Ramon, McCarthy, Helen, Mulligan, Stephen, Tedeschi, Alessandra, Castillo, Jorge J, Czyz, Jaroslaw, Fernández de Larrea, Carlos, Belada, David, Libby, Edward, Matous, Jeffrey, Motta, Marina, Siddiqi, Tanya, Tani, Monica, Trněný, Marek, Minnema, Monique C, Buske, Christian, Leblond, Veronique, Treon, Steven P, Trotman, Judith, Chan, Wai Y, Schneider, Jingjing, Allewelt, Heather, Patel, Sheel, Cohen, Aileen, Tam, Constantine S, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Dimopoulos, Meletios A, Opat, Stephen, D'Sa, Shirley, Jurczak, Wojciech, Lee, Hui-Peng, Cull, Gavin, Owen, Roger G, Marlton, Paula, Wahlin, Björn E, Garcia-Sanz, Ramon, McCarthy, Helen, Mulligan, Stephen, Tedeschi, Alessandra, Castillo, Jorge J, Czyz, Jaroslaw, Fernández de Larrea, Carlos, Belada, David, Libby, Edward, Matous, Jeffrey, Motta, Marina, Siddiqi, Tanya, Tani, Monica, Trněný, Marek, Minnema, Monique C, Buske, Christian, Leblond, Veronique, Treon, Steven P, Trotman, Judith, Chan, Wai Y, Schneider, Jingjing, Allewelt, Heather, Patel, Sheel, Cohen, Aileen, and Tam, Constantine S

Published
2023

4. How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia

Author

Deodato, Marina, Frustaci, Anna Maria, Sportoletti, Paolo, Laurenti, Luca, Murru, Roberta, Visentin, Andrea, Reda, Gianluigi, Mauro, Francesca Romana, Quaresmini, Giulia, Vanazzi, Anna, Vitale, Candida, Orsucci, Lorella, Massaia, Massimo, Sanna, Alessandro, Motta, Marina, Ibatici, Adalberto, Ferrarini, Isacco, Borella, Chiara, Varettoni, Marzia, Tani, Monica, Marinoni, Sara, Ferrario, Andrea, Zamprogna, Giulia, Montillo, Marco, Tedeschi, Alessandra, Laurenti, Luca (ORCID:0000-0002-8327-1396), Deodato, Marina, Frustaci, Anna Maria, Sportoletti, Paolo, Laurenti, Luca, Murru, Roberta, Visentin, Andrea, Reda, Gianluigi, Mauro, Francesca Romana, Quaresmini, Giulia, Vanazzi, Anna, Vitale, Candida, Orsucci, Lorella, Massaia, Massimo, Sanna, Alessandro, Motta, Marina, Ibatici, Adalberto, Ferrarini, Isacco, Borella, Chiara, Varettoni, Marzia, Tani, Monica, Marinoni, Sara, Ferrario, Andrea, Zamprogna, Giulia, Montillo, Marco, Tedeschi, Alessandra, and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

NA

Published
2022

5. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: The ASPEN study

Author

UMC Utrecht Holding, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Tam, Constantine S, Opat, Stephen, D'Sa, Shirley, Jurczak, Wojciech, Lee, Hui-Peng, Cull, Gavin, Owen, Roger G, Marlton, Paula, Wahlin, Björn Engelbrekt, Garcia-Sanz, Ramon, McCarthy, Helen, Mulligan, Stephen, Tedeschi, Alessandra, Castillo, Jorge, Czyz, Jaroslaw, Fernández de Larrea, Carlos, Belada, David, Libby, Edward, Matous, Jeffrey V, Motta, Marina, Siddiqi, Tanya, Tani, Monica, Trneny, Marek, Minnema, Monique C, Buske, Christian, Leblond, Veronique, Chan, Wai Y, Schneider, Jingjing Yan, Ro, Sunhee, Cohen, Aileen, Huang, Jane, Dimopoulos, Meletios A, UMC Utrecht Holding, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Tam, Constantine S, Opat, Stephen, D'Sa, Shirley, Jurczak, Wojciech, Lee, Hui-Peng, Cull, Gavin, Owen, Roger G, Marlton, Paula, Wahlin, Björn Engelbrekt, Garcia-Sanz, Ramon, McCarthy, Helen, Mulligan, Stephen, Tedeschi, Alessandra, Castillo, Jorge, Czyz, Jaroslaw, Fernández de Larrea, Carlos, Belada, David, Libby, Edward, Matous, Jeffrey V, Motta, Marina, Siddiqi, Tanya, Tani, Monica, Trneny, Marek, Minnema, Monique C, Buske, Christian, Leblond, Veronique, Chan, Wai Y, Schneider, Jingjing Yan, Ro, Sunhee, Cohen, Aileen, Huang, Jane, and Dimopoulos, Meletios A

Published
2020

6. Italian real-life experience with brentuximab vedotin: Results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma

Author

Broccoli, Alessandro, Pellegrini, Cinzia, Di Rocco, Alice, Puccini, Benedetta, Patti, Caterina, Gini, Guido, Mannina, Donato, Tani, Monica, Rusconi, Chiara, Romano, Alessandra, Vanazzi, Anna, Botto, Barbara, Carlo-Stella, Carmelo, Hohaus, Stefan, Musto, Pellegrino, Mazza, Patrizio, Molica, Stefano, Corradini, Paolo, Fama, Angelo, Gaudio, Francesco, Merli, Michele, Gravetti, Angela, Gritti, Giuseppe, Arcari, Annalisa, Tosi, Patrizia, Liberati, Anna Marina, Pinto, Antonello, Pavone, Vincenzo, Gherlinzoni, Filippo, Naso, Virginia, Volpetti, Stefano, Trentin, Livio, Goldaniga, Maria Cecilia, Bonfichi, Maurizio, De Renzo, Amalia, Schiavotto, Corrado, Spina, Michele, Storti, Sergio, Carella, Angelo Michele, Stefoni, Vittorio, Argnani, Lisa, Zinzani, Pier Luigi, Hohaus, Stefan (ORCID:0000-0002-5534-7197), Storti, Sergio (ORCID:0000-0002-4374-3985), Broccoli, Alessandro, Pellegrini, Cinzia, Di Rocco, Alice, Puccini, Benedetta, Patti, Caterina, Gini, Guido, Mannina, Donato, Tani, Monica, Rusconi, Chiara, Romano, Alessandra, Vanazzi, Anna, Botto, Barbara, Carlo-Stella, Carmelo, Hohaus, Stefan, Musto, Pellegrino, Mazza, Patrizio, Molica, Stefano, Corradini, Paolo, Fama, Angelo, Gaudio, Francesco, Merli, Michele, Gravetti, Angela, Gritti, Giuseppe, Arcari, Annalisa, Tosi, Patrizia, Liberati, Anna Marina, Pinto, Antonello, Pavone, Vincenzo, Gherlinzoni, Filippo, Naso, Virginia, Volpetti, Stefano, Trentin, Livio, Goldaniga, Maria Cecilia, Bonfichi, Maurizio, De Renzo, Amalia, Schiavotto, Corrado, Spina, Michele, Storti, Sergio, Carella, Angelo Michele, Stefoni, Vittorio, Argnani, Lisa, Zinzani, Pier Luigi, Hohaus, Stefan (ORCID:0000-0002-5534-7197), and Storti, Sergio (ORCID:0000-0002-4374-3985)

Abstract

Between November 2012 and July 2014, in accordance with national law 648/96, brentuximab vedotin was available in Italy for patients with relapsed systemic anaplastic large cell lymphoma outside a clinical trial context. A large Italian observational retrospective study was conducted on the use of brentuximab vedotin in everyday clinical practice to check whether clinical trial results are confirmed in a real-life context. The primary endpoint of this study was best response; secondary endpoints were the overall response rate at the end of the treatment, duration of response, survival and safety profile. A total of 40 heavily pretreated patients were enrolled. Best response was observed after a median of four cycles in 77.5%: globally, 47.5% patients obtained a complete response, 64.2% in the elderly subset. The overall response rate was 62.5%. At the latest follow up, 15/18 patients are still in complete remission (3 with consolidation). The progression-free survival rate at 24 months was 39.1% and the disease-free survival rate at the same time was 54% (median not reached). All the long-term responders were aged <30 years at first infusion. The treatment was well tolerated even in this real-life context and no deaths were linked to drug toxicity. Brentuximab vedotin induces clinical responses quite rapidly, i.e. within the first four cycles of treatment in most responders, thus enabling timely use of transplantation. For patients ineligible for transplant or for those in whom a transplant procedure failed, brentuximab vedotin may represent a feasible effective therapeutic option in everyday clinical practice.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results